Treatment of patients with neck lymph node metastasis of squamous cell carcinoma (SCC) from unknown primary tumor (NSCCUP) is challenging due to the risk of missing occult tumors or inducing toxicity to unaffected sites. Human papillomavirus (HPV) is a promising biomarker given its causal link to oropharyngeal SCC and superior survival of patients with HPV-driven oropharyngeal SCC and NSCCUP. Identification of HPV-driven NSCCUP could focus diagnostic work-up and treatment on the oropharynx. For the first time, we assessed HPV antibodies and their prognostic value in NSCCUP patients. Antibodies against E6 and E7 (HPV16/18/31/33/ 35), E1 and E2 (HPV16/18) were assessed in 46 NSCCUP patients in sera collected at diagnosis, and in follow-up sera from five patients. In 28 patients, HPV tumor status was determined using molecular markers (HPV DNA, mRNA and cellular p16 ). Thirteen (28%) NSCCUP patients were HPV-seropositive for HPV16, 18, 31, or 33. Of eleven patients with HPV-driven NSCCUP, ten were HPV-seropositive, while all 17 patients with non-HPV-driven NSCCUP were HPV-seronegative, resulting in 91% sensitivity (95% CI: 59-100%) and 100% specificity (95% CI: 80-100%). HPV antibody levels decreased after curative treatment. Recurrence was associated with increasing levels in an individual case. HPV-seropositive patients had a better overall and progression-free survival with hazard ratios of 0.09 (95% CI: 0.01-0.42) and 0.03 (95% CI: 0.002-0.18), respectively. For the first time, seropositivity to HPV proteins is described in NSCCUP patients, and high sensitivity and specificity for HPV-driven NSCCUP are demonstrated. HPV seropositivity appears to be a reliable diagnostic and prognostic biomarker for patients with HPV-driven NSCCUP.
Introduction
Neck squamous cell carcinoma from unknown primary tumor (NSCCUP) is a clinically challenging head and neck cancer subset. Patients present with a lymph node metastasis in the neck without evidence for a primary tumor despite of an extended diagnostic work-up. Occult primary tumors can be hidden in the oropharynx, particularly in the crypts of the tonsils and the base of tongue. Treatment generally includes a neck dissection that may be followed by irradiation of the neck and potential primary sites, and/or chemotherapy in advanced stages. These multimodal approaches often induce severe side effects. Reliable and easily accessible biomarkers are needed to guide the search for the primary tumor and the choice and extent of treatment.
Among the most promising biomarkers in NSCCUP is the human papillomavirus (HPV). 1 HPV, in particular HPV type 16 , is causally associated with a subset of oropharyngeal squamous cell carcinomas (OPSCC). 2 HPV-driven tumors are frequent among OPSCC, but are rare among other head and neck cancers. 3 The favorable prognosis of patients with HPV-driven versus non-HPV-driven OPSCC 4,5 provides a rationale for treatment de-escalation strategies currently assessed in clinical trials. HPV has been detected in metastases from an increasing proportion of NSCCUP patients, 6 where it might indicate an occult oropharyngeal primary tumor and a better prognosis. [6] [7] [8] [9] Although detection of HPV mRNA is the gold standard for defining HPV-driven OPSCC in research, 5 in clinical settings and studies using formalin-fixed, paraffin-embedded (FFPE) tissue this is often replaced by the detection of HPV DNA and/ or overexpression of the cellular surrogate marker p16 INK4a .
The combination of those markers gives mostly comparable results, 10 whereas the single markers have limited specificity.
5,11
An emerging minimal-invasive diagnostic method without need of tumor tissue is the detection of antibodies against HPV early proteins in serum, which are strongly associated with OPSCC. 12, 13 In our two recent studies, HPV16 E6 seropositivity had a very high sensitivity and specificity for HPV16-driven OPSCC. 14, 15 Furthermore, E6 and E7 seropositivity is associated with better survival in OPSCC patients. [16] [17] [18] HPV16 E6
antibodies were highly elevated and stable up to 13 years prior to OPSCC diagnosis. 19 After curative treatment of HPVpositive OPSCC, antibody levels were reported to decline. 18, 20, 21 In patients with non-HPV-driven tumors and in healthy individuals, the prevalence of antibodies against HPV early proteins is low. 13, 14, 16 However, in NSCCUP patients, presence of HPV antibodies and their sensitivity and specificity for HPV-driven NSCCUP have not yet been studied. Aim of this study was to assess HPV antibody patterns in NSCCUP patients at the time of diagnosis and their role as predictors for survival. Furthermore, antibody kinetics after treatment were studied in follow-up samples of HPVseropositive patients with and without recurrence. We report a high sensitivity and specificity of HPV seropositivity for HPVdriven NSCCUP that is linked to a favorable prognosis. Our results demonstrate HPV seropositivity being a reliable marker for HPV-driven NSCCUP and open up discussion for its potential application in NSCCUP diagnosis and therapeutic decision-making.
Materials and Methods

Patients
Forty-six NSCCUP patients diagnosed between 2008 and 2016 at the University Hospital Leipzig with serum collected at the time of diagnosis were included. In general, each patient underwent neck dissection and bilateral tonsillectomy, and around twenty biopsies from the base of tongue were taken and histologically examined. Neck dissection was the only treatment in ten patients (23%), eleven patients (25%) received radio-or chemotherapy, and 21 patients (48%) received chemoradiotherapy (Table 1) . One patient (ID 4) received lymphadenectomy instead of neck dissection followed by radiotherapy, one (ID 58) received lymphadenectomy without tonsillectomy and rejected further treatment, one (ID 56) died before treatment, and for one case information about radio-or chemotherapy was unavailable (ID 11). Although serum was available from all 46 patients, access to FFPE tumor tissues was limited to 28 patients. These 28 patients were not significantly different from the remaining 18 patients regarding patient and tumor characteristics (Supporting Information Table S1 ). The study was approved by the ethics committee of the Medical Faculty of the University of Leipzig (study codes: 201-10-12072010, 202-10-12072010). All patients gave informed consent.
HPV multiplex serology
HPV antibodies were detected in serum samples by bead-based multiplex serology as previously described. 22 HPV proteins (E6, E7 of HPV16/18/31/33/35 and E1, E2 of HPV16/18) were bacterially expressed as glutathione S-transferase fusion proteins bound to fluorescence-labelled glutathione-casein beads and were combined with sera in a 1:100 dilution. Serial samples were additionally tested in 1:1,000 and 1:10,000 dilutions to avoid saturation effects. Bound antibodies were detected using a biotinylated anti-human immunoglobulin antibody with fluorescent reporter conjugate. Median fluorescence intensity (MFI) was measured with a Luminex analyzer and presence of antibodies was determined based on pre-defined cut-off values (Supporting Information Table S2 ). 16 HPV seropositivity was defined by (i) high antibody levels against E6 (MFI > 1,000, HPV type defined by maximum MFI), or (ii) presence of antibodies against type-concordant E6 and E7 of HPV31/33/35
What's new?
In patients with lymph node metastasis in the neck originating from squamous cell carcinoma from unknown primary tumor (NSCCUP), detection of human papillomavirus (HPV) points to an oropharyngeal localization of the primary tumor and improved prognosis. Here the authors show that specific HPV antibody patterns identify HPV-driven tumors with high sensitivity and specificity and predict better overall and progression-free survival. The method could help to focus diagnostic work-up and treatment of NSCCUP patients.
(HPV type defined by maximum MFI), or (iii) antibodies against at least three type-concordant early antigens of HPV16/ 18. Antibodies against the major capsid proteins VP1 of human polyomaviruses BK, JC, and Merkel cell polyomavirus (MCPyV) were detected as controls.
Molecular HPV detection in tumor tissue
Genomic DNA and RNA were extracted from FFPE tumor sections as previously described. 6 HPV L1 DNA was amplified by BSGP51/61-PCR followed by hybridization of PCR products to type-specific probes (51 HPV types) and detection with a Luminex analyzer.
23 E6*I mRNA of HPV16 and other encountered types was detected by RT-PCR followed by hybridization to splice product-specific probes. 24 Nucleic acid integrity was validated by human b-globin DNA and ubiquitin C RNA detection. Cellular p16
INK4a was detected in tissue sections as previously described. 6 Overexpression was defined by nuclear and/or cytoplasmic staining of 25-70% (intermediate) or >70% (high) of tumor cells. HPV-driven NSCCUPs were defined by presence of HPV mRNA together with HPV DNA and/or p16
INK4a overexpression.
Statistical analysis
Patient and tumor characteristics were obtained from clinical records. Survival was assessed using the Kaplan-Meier method and multivariable Cox proportional hazard regression models. Firth's penalized likelihood method was applied to mitigate convergence problems arising from the fact that only male patients experienced an event. P values below 0.05 were considered statistically significant. Statistical analyses were performed using R version 3.4.0.
Results
HPV antibodies present in a subset of NSCCUP patients
To study antibody patterns, sera from 46 NSCCUP patients were analyzed for antibodies against early HPV proteins. Thirteen (28%) patients were HPV-seropositive (Table 1) . Of the ten (77%) HPV16-seropositive patients, nine had high E6 antibody levels, seven had antibodies against all four HPV16 antigens and one lacked E6 antibodies, but had antibodies against the three other antigens (Table 2A) . A single case each was seropositive for HPV18, 31 and 33. Among the 33 HPVseronegative patients, 29 (88%) showed no antibody reactivity at all, whereas four reacted each to a single antigen, but did not meet the criteria for HPV seropositivity. These results demonstrate that antibodies against HPV16 and other HPV types are present in a substantial proportion of NSCCUP patients.
Characteristics of HPV-seropositive patients
To investigate whether HPV-seropositive NSCCUP patients represent an epidemiologically and/or clinically distinct subset, patient characteristics were compared between HPVseropositive and HPV-seronegative patients (Table 1) . No significant differences were observed regarding sex and age at diagnosis. While alcohol consumption was equally common (85 vs 91%, p 5 0.6), tobacco consumption was significantly less frequent among HPV-seropositive patients (46 vs 91%, p 5 0.003). HPV-seropositive patients tended to present with less advanced disease indicated by less advanced nodal stage (N2b/2c/3, 46 vs 72%, p 5 0.1) and less extracapsular spread (55 versus 84%, p 5 0.09).
High sensitivity and specificity of HPV seropositivity for HPV-driven NSCCUP
To evaluate the potential of HPV antibodies as diagnostic marker for HPV-driven NSCCUP, metastases from 28 patients were analyzed for molecular HPV markers. Eleven patients had HPV-driven metastases (nine HPV16-driven, one HPV31-driven, and one HPV33-driven) defined by presence of HPV mRNA in combination with HPV DNA and/or p16 INK4a overexpression (Table 2A) . The nine patients with HPV16-driven metastases had significantly increased antibody levels against four HPV16 antigens compared to the 17 patients with non-HPV-driven metastases (Supporting Information Fig. S1 ). However, notably 2/9 HPV-driven NSCCUP patients (22%) did not have antibodies to all four antigens (Table 2A ). All nine patients with HPV16-driven metastases were HPV16-seropositive, resulting in a sensitivity of 100% (95% CI: 66-100%) for HPV16-driven metastases. The patient with an HPV31-driven metastasis had HPV31 E6 and E7 antibodies, and was thus HPV31-seropositive, while the patient with an HPV33-driven metastasis had HPV33 E7 but no E6 antibodies and was defined HPV-seronegative (Table  2A) . Due to this discordant case, the overall sensitivity of HPV seropositivity for HPV-driven NSCCUP was 91% (95% CI: 59-100%, Supporting Information Table S3 ). All 17 patients with non-HPV-driven metastases were HPVseronegative (Table 2B) , resulting in a specificity of 100% (95% CI: 80-100%). The positive predictive value was 100%, and the negative predictive value ranged between 94% (95% CI: 72-99%) for any HPV type and 100% for HPV16. These 
results show that NSCCUP driven by HPV16 or other HPV types can be identified by HPV serology with high sensitivity and specificity.
Survival benefit of HPV-seropositive patients
To assess the prognostic value of HPV seropositivity in NSCCUP patients, survival was compared for HPVseropositive versus HPV-seronegative patients. HPVseropositive patients showed significantly better overall survival (OS, p 5 0.004) and progression-free survival (PFS, p 5 0.02, Fig 1) . Multivariate analysis confirmed the survival benefit of HPV-seropositive patients after adjusting for the potential confounders, i.e. sex, age at diagnosis, tobacco and alcohol consumption, nodal stage, extracapsular spread, and treatment (Supporting Information Table S4 ). The hazard ratio (HR) for HPV-seropositive patients was 0.09 (95% CI: 0.01-0.40, p < 0.001) for OS, and 0.03 (95% CI: 0.002-0.17, p < 0.001) for PFS. In addition, multivariate analysis 
a n y -----n a n a n a 1 1 a n y -----n a n a n a 1 2 a n y -----n a n a n a 1 5 a n y -----n a n a n a 1 7 a n y -----n a n a n a 3 3 a n y -----n a n a n a 3 5 a n y -----n a n a n a 3 6 a n y -----n a n a n a 3 7 a n y -----n a n a n a 4 1 a n y -----n a n a n a 5 1 a n y -----n a n a n a 5 2 a n y -----n a n a n a 5 3 a n y -----n a n a n a 5 7 a n y -----n a n a n a 6 0 revealed multimodal treatment (postoperative chemoradiotherapy) as favorable prognostic factor for PFS (HR 5 0.04, 95% CI: 0.003-0.26, p < 0.001). Unfavorable prognostic factors were extracapsular spread (HR 5 6.24, 95% CI: 1.22-86.5, p 5 0.03), and increased age at diagnosis (HR 5 1.09, 95% CI: 1.02-1.18, p 5 0.008, Supporting Information Table  S4 ). These data demonstrate the potential of HPV seropositivity as biomarker for better prognosis in NSCCUP patients.
HPV antibody levels decrease after treatment in HPV-seropositive patients
To study HPV antibody kinetics after treatment in NSCCUP patients, we measured antibody levels in follow-up sera collected within five years after treatment from four HPVseropositive patients without recurrence and one patient with recurrence. An initial decrease of HPV antibody levels was observed in all four recurrence-free patients within one year after treatment (Supporting Information Fig. S2A ), but not for antibodies against the control antigens from BK, JC, and MCPyV (Supporting Information Fig. S3 ). In two patients with longer follow-up (ID 16, ID 18), the main decrease in HPV antibody levels was observed within the first 18 months, reaching between 48 and 75%, while within the following 18 months antibody levels decreased only by additional 10-14%. HPV antibodies were still detectable even 5 years after treatment and all patients remained HPV-seropositive during follow-up. These data indicate that an initial decrease in HPV antibody levels after treatment is followed by a plateau phase for several years in HPV-seropositive patients without recurrence.
One further HPV16-seropositive patient, who received surgical treatment but declined chemoradiotherapy, was subsequently diagnosed with a base of tongue carcinoma at month 15 post-treatment. After resection of the HPV16-driven carcinoma, likely the primary tumor, the patient presented again with new lymph node metastases that were resected at month 29. At month 15, the HPV16 antibody levels were decreased to 64-82% (Supporting Information Fig.  S2B ), but at month 35, levels of E7, E1 and E2 were increased to similar levels as observed at initial NSCCUP diagnosis (81-121%) and decreased again to 38-72% in the following 18 months. The antibody dynamics in this patient suggest the possibility that increasing antibody levels after treatment might indicate tumor recurrence.
Discussion
This study presents the first evidence for HPV antibody patterns identified in patients with HPV-driven NSCCUP. We report a high sensitivity and very high specificity of HPV seropositivity for HPV-driven NSCCUP. To our knowledge, this is the first study assessing HPV antibodies in NSCCUP patients, whereas HPV16 antibodies have been comprehensively studied in OPSCC patients, revealing similar antibody patterns. The fact that antibody patterns strongly associated with HPV-driven OPSCC, are present in patients with HPV-driven NSCCUP, is supporting previous suggestions that HPV-driven NSCCUP are most likely derived from the oropharynx. 1, 7, 9 We could validate the Figure 1 . Survival of NSCCUP patients in relation to HPV serostatus. Kaplan-Meier curves for OS (left) and PFS (right) with 95% CIs (shaded areas) are compared for HPV-seropositive (sero1, gray) versus HPV-seronegative (sero-, black) patients. The numbers of patients at risk are depicted below the graph. p values were calculated using log-rank test. Multivariate analysis was performed to calculate the hazard ratio (HR) adjusted by sex, age at diagnosis, tobacco and alcohol consumption, nodal stage, extracapsular spread, and treatment (Supporting Information Table S4 ).
recently suggested algorithm to define HPV16-seropositive patients by (i) high HPV16 E6 antibody levels, or (ii) antibodies against at least three early proteins. 14, 15 This algorithm had shown a sensitivity of 97% (95% CI: 90-99%) and specificity of 98% (95% CI: 90-100%) for HPV16-driven OPSCC, 14 and reached in this study a sensitivity and specificity of 100% (95% CI: 59-100%) for HPV16-driven NSCCUP. Interestingly, this study also identified a single patient lacking E6 antibodies, but having antibodies against the three other HPV16 early proteins analyzed, emphasizing the significance of the two-part algorithm. No previous algorithms are reported for non-HPV16 types. Assessment of antibodies against four HPV18 early proteins enabled us to apply the algorithm used for HPV16. Nevertheless, the algorithms we suggest here for HPV18/31/33/35 are explorative and need to be validated in larger studies including tumors driven by those types, which however represent only about 11% of HPV-driven NSCCUP. 6 In a limited number of follow-up serum samples from HPV-seropositive patients, we observed the strongest decrease in antibody levels within one year after treatment, but patients remained HPV-seropositive during follow-up. This resembles the antibody kinetics described for OPSCC patients. 17, 18, 20, 21 The single patient with recurrence indicated that increasing antibody levels after the initial drop might predict recurrence, which is in line with the lower HPV E6 and E7 antibody clearance reported for patients with recurrent OPSCC. 25 By identifying patients with HPV-driven NSCCUP with high sensitivity and specificity, HPV serology demonstrated its strong prognostic value. HPV-seropositive patients had a >10-fold reduced risk of death and progression in multivariate analysis, which is supporting the recently reported survival benefit of patients with HPV-driven NSCCUP. 6 Serum antibody patterns are particularly suitable biomarkers due to the accessibility without need for biopsies. The substantial proportion of HPV-seropositive patients and the high sensitivity and specificity for HPV-driven NSCCUP suggest the application of antibody detection in NSCCUP diagnostic work-up, which encourages the development of easy-to-perform and cost-effective serological assay platforms for clinical settings. HPV serology might conceivably replace molecular HPV detection in future. However, additional studies are required comparing serological and molecular HPV markers, since this study was limited in number of patients. A better survival of HPV-seropositive NSCCUP patients may allow for treatment de-escalation, which needs to be carefully evaluated in prospective trials. A change in management might hopefully improve treatment tolerability and quality of life in patients with HPV-driven NSCCUP.
